Загрузка...
PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer
INTRODUCTION: Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commo...
Сохранить в:
| Опубликовано в: : | Expert Rev Clin Pharmacol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6317331/ https://ncbi.nlm.nih.gov/pubmed/29641940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1464388 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|